en · de · es
lab-handbook.peptides6823.com › Wiki › Identity And Naming Background — Practical Notes

Identity And Naming Background — Practical Notes

By Editorial Desk · published 2026-04-15 · last reviewed 2026-05-14 · Wiki

Everything below concerns actin binding. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-05-14. Where a claim depends on a specific study, the study is described rather than over-claimed.

Identity And Naming Background

TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.

Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.

Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.

Research Framing and Evidence Base

Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.

Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.

Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.

Tb-500 at a glance

PropertyValueNotes
AppearanceWhite to off-white powderSupplied as a lyophilised cake in sealed vials
Solubility classFreely soluble in waterPolar and charged side chains dominate the sequence
Typical storage temperature-20 °C or belowDry and dark; a desiccant is often recommended
Identity confirmationMass spectrometryObserved mass compared with the theoretical value
Common synonymsThymosin beta-4 fragmentAlso written as T beta 4 fragment 17-23

TB-500 Identity and Molecular Background

Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.

TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.

Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.

Related pages on this site

Identity and Reported Background

TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.

Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.

Reference notes

== Scientific background == Platelet-derived growth factor (PDGF) is a signalling protein involved in wound healing, tissue repair, and angiogenesis. Research has established that PDGF stimulates chemotaxis and proliferation in monocytes, macrophages and fibroblasts, playing a key regulatory role in the tissue repair cascade. Studies have further shown that exogenous recombinant PDGF-BB significantly accelerates wound closure in both incisional and excisional wound models. Other growth factors, including transforming growth factor-β, have also been studied in experimental wound-healing models. The only PDGF-based drug currently approved by a major regulatory authority is becaplermin, sold under the brand name Regranex, a recombinant human PDGF-BB gel approved by the U.S. Food and Drug Administration (FDA) in 1997 for the treatment of diabetic neuropathic foot ulcers. As of the date of this article, no PDGF drug has been approved for commercial sale in China.

The E1 subunit, called the pyruvate dehydrogenase subunit, is either a homodimer (comprising two "α" chains, e.g. in Escherichia coli) or a heterotetramer of two different chains (two "α" and two "β" chains). A magnesium ion forms a 4-coordinate complex with three, polar amino acid residues (Asp, Asn, and Tyr) located on the alpha chain, and the thiamine diphosphate (TPP) cofactor directly involved in decarboxylation of the pyruvate.

In obese people, the relative proportion of Firmicutes (Gram-positive bacteria) in gut microbiota is increased resulting in greater conversion of the non-genotoxic primary bile acid, cholic acid, to carcinogenic deoxycholate. Exercise decreases deoxycholate in the colon. Humans whose level of physical activity placed them in the top third had a 17% decrease in fecal bile acid concentration compared to those whose level of physical activity placed them in the lowest third. Rats provided with an exercise wheel had a lower ratio of secondary bile acids to primary bile acids than sedentary rats in their feces. There is a positive association of exercise and physical activity with cancer prevention, tolerance to cancer-directed therapies (radiation and chemotherapy), reduction in recurrence, and improvement in survival.

=== Dissociation and cognitive challenges === The heightened emotional states experienced by individuals with BPD can impede their ability to concentrate and cognitively function. Additionally, individuals with BPD may frequently dissociate, which can be regarded as a mild to severe disconnection from physical and emotional experiences. Observers may notice signs of dissociation in individuals with BPD through diminished expressiveness in their face or voice, or an apparent disconnection and insensitivity to emotional cues or stimuli. Researchers disagree about whether dissociation or a sense of emotional detachment and physical experiences impact the ability of people with BPD to recall the specifics of past events. A 1999 study reported that the specificity of autobiographical memory was decreased in BPD patients. The researchers found that decreased ability to recall specifics was correlated with patients' levels of dissociation, which "may help them to avoid episodic information that would evoke acutely negative affect".

Sources: en.wikipedia.org

Notes from published material

== Causes == The pathophysiology of polymyalgia rheumatica is not well-understood. Evidence shows that there is likely a combined genetic and environmental pathophysiology behind the disease, but concrete identification of the causes, including whether or not polymyalgia rheumatica is an autoimmune disease, remains elusive. It is, at the very least, an immune-mediated disease, with both innate and adaptive immune system elements being known to play a role. Infectious diseases have historically been hypothesized as a likely trigger for disease in genetically susceptible people. Individual studies have sometimes found correlations between specific pathogens and development of the disease, but broader analysis fails to find significant correlations. Proposed causative pathogens, none of which have been proven, include:

Inducers of hepatic microsomal enzymes such as barbiturates, phenytoin, and rifampicin can reduce the half-life of dexamethasone. Cotreatment with oral contraceptives can increase its volume of distribution.

== Playwrights, screenwriters, producers, and directors == Henry Churchill de Mille (1875), playwright and Georgist; father of film pioneers Cecil B. DeMille and William C. deMille William C. deMille (1900), screenwriter, director, playwright; second president of the Academy of Motion Picture Arts and Sciences; co-founder of the USC School of Cinematic Arts Edgar Allan Woolf (1901), screenwriter, The Wizard of Oz George Middleton (1902), playwright and president of the Dramatists Guild of America Herman Mankiewicz (1917), drama critic for The New Yorker and co-winner of the Academy Award for Best Original Screenplay for Citizen Kane Morrie Ryskind* (1917), winner of the Pulitzer Prize for Drama with George S. Kaufman for Of Thee I Sing and co-writer of The Cocoanuts, Animal Crackers, and A Night at the Opera Sam Spewack (1919), winner of the Tony Award for the book of Kiss Me, Kate Sidney Buchman (1923), screenwriter for Mr. Smith Goes to Washington and winner of the Academy Award for Writing Adapted Screenplay for Here Comes Mr. Jordan Guy Endore (1923), screenwriter for The Story of G.I. Joe Alvah Bessie (1924), screenwriter for Objective, Burma! and one of the Hollywood Ten Ferrin Fraser (1927), radio scriptwriter for Little Orphan Annie and Frank Buck Joseph Mankiewicz (1928), Academy Award-winning writer and director of All About Eve and A Letter to Three Wives Frank S. Nugent (1929), screenwriter for Fort Apache, She Wore a Yellow Ribbon, and The Quiet Man Robert F.

== Logistics == To meet the testing demand both in terms of turnaround times and specimens processed per day, SHIELD Illinois created an extensive logistics network consisting of The Depot (Chicagoland Central distribution hub), funnel sites (drop points for collection sites located far from The Depot or a central Illinois laboratory), a fleet of 40 vehicles, 12 geographically disparate labs, and a courier network covering 80,000 square miles.

N-Hydroxyphthalimide is the organic compound with the formula C6H4(CO)2NOH. A white or yellow solid, it is a derivative of phthalimide. The compound is used as a catalyst in the synthesis of other organic compounds. It is soluble in water and organic solvents such as acetic acid, ethyl acetate and acetonitrile.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 identical to thymosin beta-4?

No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.

Where does the sequence LKKTETQ come from?

It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.

Is TB-500 an approved medicine?

It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.

What mechanism is most often proposed?

The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.

Network